

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from 30 October 2025, Mr. Dong Zimeng (董子銘) (“**Mr. Dong**”) was appointed as a non-executive Director.

The biographical background of Mr. Dong is as follows:

Mr. Dong, aged 40, is a seasoned finance professional with 17 years of extensive experience in domestic and international capital market investment, mergers and acquisitions, fund management, and corporate operations. Mr Dong’s expertise is in domestic and international investment and mergers and acquisitions, corporate overseas financing, and Initial Public Offering (IPO), as well as in Hong Kong capital market’s business operations and regulatory framework. Since September 2024, Mr. Dong has been the managing partner and the responsible officer of Providence Capital Group Limited, a corporation licensed to carry out type 9 (Asset Management) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)(the “**SFO**”), where he is mainly responsible for overseeing the company operations, formulating corporate strategies and managing investments. From August 2021 to September 2024, Mr. Dong served as president of the Shenzhen Capital International Co., Ltd., an investment company which is owned by Shenzhen State-Owned Assets Supervision and Administration Commission, where he headed the overall management and daily operation. From September 2015 to August 2021, Mr. Dong was the president of Co-High Asset Management Co., Ltd. and the chairman of Co-High Asset Management (Shenzhen) Co., Ltd., where he led the overall strategic direction of the companies.

Mr. Dong was awarded a Master of Science in Applied Bioengineering and a Bachelor of Engineering in Electronic Information Engineering from University of Warwick, the United Kingdom in 2008 and 2006, respectively.

Mr. Dong was nominated by Providence Discovery Fund (the “**Subscriber**”) pursuant to the subscription agreement dated 25 July 2025 entered into between the Company as issuer and Subscriber as the subscriber, under which the Subscriber shall have the right to nominate one non-executive Director to the Company.

Mr. Dong entered into a letter of appointment (“**Mr. Dong’s Letter of Appointment**”) with the Company for a fixed term of one year commencing on date of this announcement and shall be renewed and extended automatically by one year on the expiry of such initial term and on the expiry of every successive period of one year thereafter, unless terminated by either the Company or Mr. Dong giving at least three months’ written notice, subject to removal, rotation and re-election in accordance with Mr. Dong’s Letter of Appointment. Mr. Dong shall hold office until the next following annual general meeting of the Company (the “**AGM**”) and shall then be eligible for re-election by the shareholders of the Company at the AGM pursuant to article 112 of the Articles of Association of the Company (the “**Articles**”) and thereafter subject to re-election by rotation at least once every three years in accordance with article 108(a) of the Articles.

As a non-executive Director, Mr. Dong is entitled to an annual remuneration of HK\$200,000 payable by quarterly instalments in accordance with Mr. Dong’s Letter of Appointment. Mr. Dong’s remuneration package is determined by the Board according to the Group’s policy on the Directors’ and senior management’s remuneration.

As at the date of this announcement, Mr. Dong does not have any interest in any shares, underlying shares or debenture of the Company and/or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Dong does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined in the Listing Rules), and he does not hold any position in the Company or any of its subsidiaries.

Save as disclosed herein, the Board is not aware of any other matter relating to the appointment of Mr. Dong that needs to be brought to the attention of the shareholders of the Company and does not have any information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its warmest welcome to Mr. Dong in joining the Board.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 30 October 2025

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Directors are Mr. Leung Stephen Kwok Keung and Mr. Dong Zimeng; and the independent non-executive Directors are Dr. Hung Ting On, John, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.